Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer

BACKGROUND: Adjuvant zoledronate is widely used in patients with early stage breast cancer (EBC), but its optimal duration and dosing interval is still unknown. While a single-dose of zoledronate can improve bone density for many years, a proper evaluation of its effects on breast cancer-related out...

Descripción completa

Detalles Bibliográficos
Autores principales: Awan, Arif, Ng, Terry, Conter, Henry, Raskin, William, Stober, Carol, Simos, Demetrios, Pond, Greg, Dhesy-Thind, Sukhbinder, Mates, Mihaela, Kumar, Vikaash, Fergusson, Dean, Hutton, Brian, Saunders, Deanna, Vandermeer, Lisa, Clemons, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782555/
https://www.ncbi.nlm.nih.gov/pubmed/33425673
http://dx.doi.org/10.1016/j.jbo.2020.100343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782555/
https://www.ncbi.nlm.nih.gov/pubmed/33425673
http://dx.doi.org/10.1016/j.jbo.2020.100343

Ejemplares similares